Aslan to present additional data from TREK-DX study during KOL event

ASLAN Pharmaceuticals will host a virtual KOL event, during which Company management will present new data from the interim analysis of the Phase 2 TREK-DX study of eblasakimab in dupilumab-experienced atopic dermatitis patients. The KOL event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, will begin at 8:00 am ET. “The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis and the new data continue to support our original conclusions announced in April. We’re delighted to observe patient-reported outcomes, such as itch score, correlate strongly to the investigator-assessed outcomes we previously reported, including the vIGA and EASI scores,” said Dr Carl Firth, CEO. “Based on these data and the data we previously reported from the interim analysis of the TREK-DX study, we are establishing a greater understanding of how patients who did not respond to dupilumab may respond to eblasakimab, and, additionally, how eblasakimab may be effective in those AD patients who have a very limited number of safe and long-term alternatives.” In April, ASLAN announced positive interim data from 22 patients enrolled in the TREK-DX study. The primary endpoint, which is the percent change in Eczema Area Severity Index score from baseline to Week 16, was statistically significant when compared to placebo, even though the interim analysis was not powered for statistical significance due to the sample size. 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 and 66.7% achieved a vIGA score of 0 or 1 after 16 weeks, versus 14.3% of patients on placebo. During the KOL event today, Company management will present new data on investigator-assessed and patient-reported secondary endpoints and data from the subgroup of patients with prior inadequate response to dupilumab. Discontinuation rates were lower for patients treated with eblasakimab compared to those on placebo. Time courses for secondary endpoints demonstrated rapid onset of effect for patients treated with eblasakimab, with over half of patients achieving EASI-75 by Week 6 and 73% achieving EASI-75 by Week 16. These investigator assessments are further supported by patient-reported pruritus scores, which show a rapid reduction in itch, with clear separation observed as early as Week 2. Waterfall plots of individual patient responses show clear and consistent improvements in almost all patients treated with eblasakimab versus placebo. Patients with prior inadequate response to dupilumab showed mean percent change in EASI at Week 16 of 91% reduction.